Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945875 | 0.81 | LMNA (0.34) | LMNA | |
| SCHEMBL9945905 | 0.77 | ACHE (0.33) | LMNA | |
| SCHEMBL20866895 | 0.77 | LMNA (0.32) | LMNA | |
| SCHEMBL24681025 | 0.74 | TRPA1 (0.42) | LMNA | |
| SCHEMBL12360639 | 0.74 | HTR2A (0.37) | LMNA | |
| SCHEMBL17988483 | 0.74 | ALDH1A1 (0.31) | LMNA | |
| SCHEMBL19160972 | 0.74 | HPGD (0.34) | — | |
| SCHEMBL13748359 | 0.69 | TSHR (0.38) | — | |
| SCHEMBL24294003 | 0.68 | — | — | |
| SCHEMBL10304822 | 0.68 | ACHE (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192504-A1 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | LMNA 875/4885 |
| US-11040033-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | LMNA 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.